CompletedPhase 2NCT01404650

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
SCRI Development Innovations, LLC
Principal Investigator
Johanna Bendell, MD
SCRI Development Innovations, LLC
Intervention
AUY922(drug)
Enrollment
25 target
Eligibility
18 years · All sexes
Timeline
20112015

Study locations (8)

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01404650 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials